AOD-9604 raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-03 and is reviewed periodically as new material appears.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
| Property | Value | Notes |
|---|---|---|
| Common synonym | hGH fragment 176-191 | Refers to the C-terminal segment |
| Appearance | White to off-white powder | Typically supplied lyophilized |
| Solubility | Soluble in water and aqueous buffers | Confirm with technical data |
| Typical storage temperature | -20 °C for dry powder | Protect from moisture and light |
| Common analytical method | RP-HPLC with UV detection | Often paired with mass spectrometry |
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
=== Dermatologie === In der Dermatologie wird dieses Verfahren in der Akne- und Narbenbehandlung eingesetzt. Die hier verwendeten Nadeln sind bis zu 2,5 Millimeter lang. Vor der Behandlung wird das betreffende Hautareal desinfiziert und ein lokal wirkendes Betäubungsmittel aufgetragen. Nach Wirkungseintritt wird die Walze einige Male hin- und hergerollt; da hierbei tiefere Hautschichten punktiert werden, kann Blut austreten. Bei der Behandlung durchstechen die Nadeln die Haut, dies reizt die Zellen, fördert die Durchblutung der Haut und beschleunigt die Regeneration. Dauert diese normalerweise 28 Tage, so läuft der Prozess durch das Microneedling schneller ab. Auch die Bildung von Kollagen, Hyaluronsäure und Elastin wird angeregt, dies führt zu einem frischeren, glatteren und strafferem Hautbild: An den Einstichstellen bilden sich im Rahmen der Hautregeneration Kollageninseln. Durch gegenseitige Annäherung dieser Inseln wird ein Straffungseffekt erreicht, der bei frischen Narben dauerhaft anhält. Dazu sind jedoch mehrere Behandlungszyklen, zunächst im Abstand von acht bis zehn Wochen, später alle vier bis sechs Monate, nötig. Bei der Behandlung von Narbenwucherungen zerstören die Mikronadeln die alten Kollagenfasern, welche sich anschließend neu bilden.
=== Schmerzen bei der Behandlung === Abhängig davon, wie tief die Nadeln in die Haut eindringen und wie das individuelle Schmerzempfinden zum Zeitpunkt der Behandlung ist, kann das Microneedling Schmerzen verursachen. Daher tragen Kosmetiker und Dermatologen in der Regel vor der Behandlung eine Betäubungscreme auf. Das macht die Behandlung angenehmer.
== Nebenwirkungen und Gegenanzeigen == Nach der Behandlung tritt eine Rötung und ein Spannungsgefühl und / oder Brennen der behandelten Hautareale auf. Dies hält in der Regel ca. 3-5 Tage an, wobei die Reaktion von Tag zu Tag weniger wird. Es kann auch vorübergehend zu einer Schwellung, v. a. von empfindlichen Hautbereichen kommen. Weitere mögliche unerwünschte Wirkungen können allergische Reaktionen und Schmerzen sein. Bei unsachgemäßer Behandlung können Wunden oder Ekzeme entstehen, die sich unter Umständen entzünden. Durch diese Infektionen kann es zur Bildung neuen Narbengewebes kommen. Bei Hautkrebs, Keloidneigung und Hämophilie darf das Verfahren nicht angewendet werden.
Sources: de.wikipedia.org
== Entwicklung == 1995 beschrieben David S. und Norman Orentreich die „Subcutaneous Incisionless (Subcision®) Surgery“ als Verfahren zur Narbenbehandlung, zwei Jahre später verwendeten Camirand und Doucet dafür eine „Tattoo-Pistole“. 2006 entwickelte Desmond Fernandes die perkutane Kollagen-Induktionstherapie mit dem „Dermaroller“.
Sources: de.wikipedia.org
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.
No. It is a shortened peptide fragment, not the full hormone. It does not contain the entire hGH sequence and is studied for different proposed effects.
Regulatory approvals for weight loss are not established in major jurisdictions. Some human trials reported modest changes, but the evidence is limited, and it remains a research compound.
AOD-9604 is a synthetic peptide fragment of human growth hormone. It corresponds to the C-terminal region known as hGH 176-191 and is studied for metabolic effects. It is not an approved therapeutic drug.